Drugs / Patient-derived CD19- and CD22 specific CAR
Patient-derived CD19- and CD22 specific CAR
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03330691 | Nov 2017 → Sep 2023 overdue | leukemia, lymphoma | Seattle Children's Hospital | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Patient-derived CD19- and CD22 specific CAR | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03330691 ↗ |
| Action | Deplete | “The CAR enables the T-cell to recognize and kill the leukemic cell through recognition of CD19 and CD22.” NCT03330691 ↗ |
| Modality | Cell therapy | “Patient-derived CD19-specific CAR also expressing an HER2t and CD22-specific CAR T-cells also expressing an EGFRt” NCT03330691 ↗ |